Actelion receives EU approval for Tracleer

Actelion has received approval for the paediatric, dispersible formulation of its Tracleer (bosentan) treatment for pulmonary arterial hypertension (PAH) in the EU.

Therefore, Tracleer is now the only PAH therapy with an approved paediatric variant for treating youngsters from the age of two.

Dr Martine Clozel, paediatrician and chief scientific officer at Actelion, said that the company is “very proud” of its achievement, explaining that a great deal of time and effort have been invested into the treatment of PAH in children.

She added: “It has been a long, but ultimately extremely rewarding journey, which had begun even before the first marketing authorisation of Tracleer.”

Professor Maurice Beghetti, head of the pediatric cardiology unit at Hopital Des Enfants in Geneva, asserted that it is “great” to see Actelion “leading the way” in offering treatments that are specifically tailored to the younger population.

In other news from the firm, Actelion recently announced that Isaac Kobrin was to take on the newly-created position of chief medical officer in a management restructure.